Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose

Australian and New Zealand Journal of Medicine
R S ScottD W Beaven

Abstract

Acarbose, 300 mg/day, was administered over one month in a cross-over trial to 18 hyperglycemic patients aged 41-66 years with non-insulin-dependent diabetes mellitus (NIDDM). All showed "normal" or exaggerated insulin release after a glucose challenge and remained in poor control (random glucose levels greater than or equal to 13 mmol/l) despite involvement in a diabetes intervention programme and prior use of oral hypoglycemic agents. During the one month treatment with Acarbose, fasting glucose and % HbAl concentrations were not different from those observed during placebo therapy. Furthermore, glucose tolerance was unchanged by Acarbose treatment. Glucose concentrations after a 1.6 MJ test meal were reduced by Acarbose from peak values of 17.3 +/- 1.0 to 15.0 +/- 1.1 mmol/l and were associated with lower post-prandial C-peptide (CPR) and insulin responses. Nevertheless, daily insulin production, as assessed by CPR excretion rates and plasma CPR and insulin concentrations, was not reduced by Acarbose. In fact, fasting plasma insulin and CPR levels were significantly higher during Acarbose then placebo therapy. Acarbose (100-400 mg/day) was continued for six months in 12 of these patients. During treatment, post-prandial gluc...Continue Reading

References

Dec 1, 1978·European Journal of Clinical Investigation·D BaxterH Keen
May 1, 1979·The Journal of Clinical Investigation·R DeFronzoV Soman
Jan 1, 1978·Advances in Metabolic Disorders·G M Reaven, J M Olefsky
Jan 1, 1976·The American Journal of Medicine·G M ReavenJ M Olefsky
Jan 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·J R GavinD N Buell
Apr 1, 1980·Australian and New Zealand Journal of Medicine·R S ScottM J Ellis
Jan 1, 1981·The American Journal of Medicine·J M Olefsky, O G Kolterman

❮ Previous
Next ❯

Citations

Aug 1, 1991·Diabetic Medicine : a Journal of the British Diabetic Association·S MarenaG Pagano
Mar 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·N HottaN Sakamoto
May 1, 1987·Diabetes Research and Clinical Practice·R S Scott, T Donnelly
Nov 1, 1986·Diabetes Research and Clinical Practice·R S ScottJ R Bremer
Aug 1, 1994·European Journal of Clinical Investigation·M Toeller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.